Učitavanje...

Histone deacetylase inhibitors: emerging mechanisms of resistance

The histone deacetylase inhibitors (HDIs) have shown promise in the treatment of a number of hematologic malignancies, leading to the approval of vorinostat and romidepsin for the treatment of cutaneous T-cell lymphoma and romidepsin for the treatment of peripheral T-cell lymphoma by the U. S. Food...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Robey, Robert W., Chakraborty, Arup R., Basseville, Agnes, Luchenko, Victoria, Bahr, Julian, Zhan, Zhirong, Bates, Susan E.
Format: Artigo
Jezik:Inglês
Izdano: 2011
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3230675/
https://ncbi.nlm.nih.gov/pubmed/21899343
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/mp200329f
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!